Nonproprietary names adopted in 2009 for antineoplasic compounds
scimedweb
recombinant MAGE-A3 antigen-specific cancer immunotherapeutic
GSK1203486A: non-proprietary name is Astuprotimut-R;
RTA 401, CDDO: non-proprietary name is Bardoxolone;
SGN-35, cAC10-vcMMAE: non-proprietary name is Brentuximab vedotin;
SCH 727965: non-proprietary name is Dinaciclib;
CP-4055: non-proprietary name is Elacytarabine;
GSK1363089G: non-proprietary name is Foretinib;
GC1008: non-proprietary name is Fresolimumab;
CR011, CR011-vcMMAE: non-proprietary name is Glembatumumab;
ADgv EGR.TNF.11D: non-proprietary name is Golnerminogene pradenovec;
V09AB03: non-proprietary name is Ioflupane I 123;
ABT-869: non-proprietary name is Linifanib;
LY2523355; KF89617: non-proprietary name is Litronesib;
NPI-0052: non- proprietary name is Marizomib;
MGCD0103: non-proprietary name is Mocetinostat;
GSK1841157, HuMax-CD20, 2F2: non-proprietary name is Ofatumumab;
BBR 2778: non-proprietary name is Pixantrone dimaleate;
NPI-2358: non-proprietary name is Plinabulin;
AP23573, MK-8669: non-proprietary name is Ridaforolimus;
PF-04948568, CDX-110: non-proprietary name is Rindopepimut;
AZD0530: non-proprietary name is Saracatinib;
AZD0530 difumarate: non-proprietary name is Saracatinib difumarate;
ACE-011: non-proprietary name is Sotatercept;
GMX1777; EB1627: non-proprietary name is Teglarinad chloride;
SN2310: non-proprietary name is Tenifatecan;
AV-951: non-proprietary name is Tivozanib;
ARRY-334543: non-proprietary name is Varlitinib;
AR00334543, ARRY-334543, ARRY-543: non-proprietary name is Varlitinib
tosylate;
MMAE, monomethyl auristatin E: non-proprietary name is Vedotin;
ABT-888: non-proprietary name is Veliparib;
hPAM4-DOTA, IMMU-107, 90hY-PAM4: non-proprietary name is Yttrium Y 90
clivatuzumab tetraxetan;
HuMax-EGFr, 2F8: non-proprietary name is Zalutumumab
InTextoResearch, Baelen, Liège, Wallonie (Wallonia), Belgique
(Belgium) & Agence Wallonne d’Information Scientifique (AWIS) (Marc
Lacroix, scim...@mail.com)